Novo Nordisk in the expanding market of diabetes care
The Danish multinational offers an exciting growth opportunity.
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.
2020-08-17 10:34

Diabetes is a group of metabolic disorders characterized by increased levels of blood sugar over prolonged periods of time. A condition tightly related to human development - the prevalence of diabetes has risen specially in places with important wealth, industrial, and economic growth.

There are two main types of diabetes: Type 1 (T1D) diabetes, previously referred to as “insulin-dependent diabetes”, constitutes 5.2% of all diagnosed cases in the US. Type 2 (T2D) diabetes is associated with body weight and exercise, and it accounts for 90% of all diabetic patients. In 2019 there were over 463 million diabetic patients worldwide, a number expected to almost double during the next 25 years. In the US only, it is estimated that 10.5 % of the population is living with diabetes.

Novo Nordisk in the expanding market of diabetes care

An increasing number of health organizations are developing programs and driving funds towards health awareness. In the US, the National Institute of Health spends yearly $1 billion in diabetes research alone. Current healthcare spending in diabetes is upwards of $700 billion annually, and with the current epidemiological trends, the expanding market of diabetes care offers a number of opportunities for investors.

The diabetes care drug market ($69.7 billion) is dominated by insulin, as it is needed by all T1D patients and approximately 20% of T2D patients, totaling 100 million people worldwide. Insulin manufacturers hold the vast majority of the diabetes care market.

NovoNordisk (NASDAQ: NVO) - The Danish multinational controls 47% of the global insulin market, and have seen their sales driven up by mid-single digits consistently over the last three years. With a short-lived drop due to the COVID pandemic, NVO share price increased over 30% in the last year. Although their revenue looks flat YoY, their Q2 net income rose 11% over Q2 2019 reaching $1.7 billion.

Their non-insulin drugs seem to be on the right path also. Ozempic, a GLP-1 receptor drug, injected weekly to manage blood sugar levels in T2D, quadrupled in sales since 2018 when it entered the market, reaching $1.78 billion by the end of 2019. Their new oral drug, Rybelsus, has brought $64.5 million in revenue sin approved by FDA at the end of 2019. Also approved by the Japanese Ministry of Health, Labor and Welfare less than a month ago, Rybelsus is the first not injected GLP-1 receptor treatment approved in the US. NVO also holds leading positions in the Obesity and Haemophilia drug markets.

Together with their solid earnings report for Q2 2020, in which NVO announced a semi-annual dividend of $0.78, the company was able to restart their Phase III trials for a Haemophilia treatment. Based on their continued success in the pharmaceutical pipeline, their consistent sales growth, and the robust lineup of current and in-development products, NVO offers an exciting growth opportunity in the expanding market of diabetes care.


Diabetes care market will continue to grow based on the rising prevalence of diabetes and the increasing number of programs in diabetes awareness. NVO hold the leading position in diabetes drug care - 47% of the global insulin market. Non-insulin drugs are driving sales up, novel treatment approved by FDA. NVO has a good growth potential and represents a good risk/reward opportunity.

Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

Published On
2020-08-17 10:34

About the Author
Alcides is a Cell Bio graduate, finishing a PhD in Neuroscience. Writes about life sciences, pharma, and biotech.

You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

NVIDIA Earnings: Will They Even Matter?
Let’s examine the bear and bull case for NVIDIA’s earnings next Wednesday.
By Mike Sakuraba | 2 weeks ago

2 Stocks I'm Avoiding as Markets Hit New All-Time Highs
People like to throw around the term bubble a lot when the market goes up a large amount in a short time. But is it really a bubble or did they just miss out on the action? I usually say it’s the latter.
By Mike Sakuraba | 3 weeks ago

2 Earnings Calls I'm Watching Next Week
It’s been a while since I’ve done this but it was a good practice and forced me to actually listen to the earnings calls of companies I invest in.
By Mike Sakuraba | 3 weeks ago

2 Stocks You Can Still Buy at All-Time Highs
For some reason, we have always been taught to try and buy low and sell high. While that might seem logical, it is a good way to miss out on buying some of the best stocks.
By Mike Sakuraba | 3 weeks ago

24 Assets to Invest in for 2024: Part 7
In Part 6, I spoke about chip stocks, Axon (NASDAQ: AXON),Celsius (NASDAQ: CELH),and the iShares Bitcoin Trust (NASDAQ: IBIT).
By Mike Sakuraba | 4 weeks ago

2 Stocks I'm Buying When Markets Pull Back
Here are 2 stocks I’m prepared to pull the trigger on as soon as the market pulls back.
By Mike Sakuraba | 4 weeks ago

24 Assets to Invest in for 2024: Part 8
In Part 7, I spoke about Rivian (NASDAQ: RIVN),Chainlink, and Evolution AB (OTC: EVVTY)
By Mike Sakuraba | 4 weeks ago

Tesla Bears Rejoice: Another Bad Quarter from Tesla
I think the next year or two is going to be tough for the company and the stock.
By Mike Sakuraba | 1 month ago